Krystal Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 32% year-over-year revenue growth to $116.4M, with strong VYJUVEK performance in the U.S., Europe, and Japan, 95% gross margin, and net income of $55.9M. Six clinical data readouts, including two registrational studies, are expected before year-end.
-
VYJUVEK's Q4 growth was driven by U.S. sales force expansion and a label update for at-home dosing, with ROW sales expected to lead 2026 growth. Pipeline programs in ocular and NK are advancing pivotal trials with increased dosing frequency, and the CF program is progressing through positive FDA discussions.
-
PTC exceeded 2025 revenue guidance, driven by a strong global launch of Sephience, which is showing broad uptake and high refill rates across PKU patient segments. The company expects continued Sephience momentum, international expansion, and progress in its Huntington’s and early-stage R&D programs, aiming for cash flow breakeven in 2026.
-
Interim results from the Phase 1 CORAL-1 study of inhaled KB407 in cystic fibrosis showed successful, broad, and durable delivery of full-length CFTR to patient airways, with over 29% of cells transduced and a favorable safety profile. Plans are underway for a registrational repeat dosing study focused on functional lung improvement.
Fiscal Year 2025
-
VYJUVEK delivered strong revenue growth in Q4 and 2025, driven by U.S. and accelerating ex-U.S. launches, with gross margins at 94% and robust net income. Pipeline progress, global expansion, and new FDA designations position the company for continued growth in 2026.
-
VYJUVEK continues global expansion with strong U.S. and Japan launches, robust pricing, and a solid financial position. Pipeline progress includes blinded ocular DEB and NK studies with clean safety profiles, and additional programs in CF, AATD, oncology, and Hailey-Hailey disease.
-
VYJUVEK revenue grew to $97.8M in Q3 2025, driven by U.S. and early European launches, with gross margin rising to 96%. Updated U.S. label, strong reimbursement trends, and pipeline progress support a positive outlook, while cash reserves exceed $864M.
-
U.S. launch shows strong patient outcomes but follows a non-linear adoption curve, with sales force expansion and label updates aimed at improving reach and compliance. Multiple global launches and a robust pipeline, including ocular and neurotrophic keratitis programs, are progressing, with key regulatory milestones and data readouts expected over the next year.
-
Q2 2025 saw $96M in VYJUVEK revenue, 9% sequential growth, and $38.3M net income. U.S. growth was driven by patient restarts and Salesforce expansion, with European and Japanese launches set to boost future revenue. Over $820M in cash supports ongoing R&D and global expansion.
-
Phase 1 results for KB304 in decolletage wrinkles showed strong safety and efficacy, with 100% investigator-assessed improvement and high subject satisfaction. The therapy replenishes collagen III and elastin, addressing aging skin at its root, and is set for Phase 2 development in early 2026.
-
First patient dosed in the Phase I-II Emerald-1 study of KB801 for neurotrophic keratitis. Preclinical data show superior and sustained NGF delivery versus current therapy, supporting a twice-weekly dosing regimen. The study targets safety, efficacy, and potential for expedited development.
-
Vyjuvek's U.S. launch is outperforming compliance expectations, with expanded sales efforts and a label change for self-administration underway. European launch is set for Q3, and pipeline programs in the eye and lung are advancing, supported by strong safety and regulatory momentum.
-
Vyjuvek's US launch remains strong despite Q1 revenue fluctuations, with European and Japanese launches set for later this year and pricing expected at 70-75% of US levels. Pipeline focus is on lung and eye therapies, with key data readouts and new trials planned in 2024-2025.
-
Q1 2025 saw VYJUVEK revenue nearly double year-over-year to $88.2M, with strong gross margins and robust U.S. patient access. European and Japanese launches are on track, and the company remains well-capitalized to support global expansion and a broad clinical pipeline.
-
VYJUVEK is set for a second-half EU launch with an improved label, targeting Germany and France first. Pricing strategies are conservative, with strong value arguments for rare disease markets. Pipeline progress includes upcoming data for ocular DEB, cystic fibrosis, oncology, and AATD.
Fiscal Year 2024
-
VYJUVEK's U.S. launch drove strong 2024 results, with $290.5M revenue and $3.12 EPS, while global expansion and pipeline progress position the company for continued growth. Over 510 U.S. reimbursement approvals and robust cash reserves support ambitious 2025 milestones.
-
Positive interim results show KB408 and KB407 are well tolerated and achieve efficient gene delivery to the lung, with KB408 demonstrating high AAT expression and functional impact in AATD patients. The programs are advancing to higher doses and redosing, with regulatory discussions planned for accelerated approval.
-
Vyjuvek's US launch has surpassed expectations, with strong compliance and ongoing international expansion. Clinical pipeline progress includes imminent readouts in AAT and CF, while strategic focus remains on lung redosing and new indications.
-
The session highlighted a robust HSV-1 gene therapy platform with strong patent protection, a successful Vyjuvek launch, and expansion plans for Europe and Japan. Pipeline progress includes ocular, respiratory, oncology, and aesthetics programs, with multiple data readouts expected in 2024-2025.
-
The session highlighted progress in rare disease gene therapies, with Vyjuvek's global expansion, upcoming KB408 data, and a robust pipeline in CF and oncology. Financials remain strong, supporting continued growth and new launches through 2025.
-
Key data from the Alpha-1 antitrypsin program are expected by year-end, guiding next steps for redosing or further cohorts. Oncology biomarker data will also be released, while commercial and global expansion efforts for VYJUVEK remain on track, with strong compliance and patient identification strategies.
-
Q3 2024 saw strong VYJUVEK revenue growth, high gross margins, and continued profitability, with over 460 U.S. patients approved and global expansion on track for 2025. Pipeline progress and a robust cash position support long-term growth.
-
A gene therapy platform has seen strong U.S. launch performance for DEB, with home dosing and high compliance. European and Japanese launches are planned, with ex-U.S. pricing at 50-70% of U.S. levels. Key clinical readouts for AATD and immuno-oncology are expected by year-end.
-
Interim data show KB301 gene therapy significantly improves wrinkles and skin quality in both lateral canthal lines and décolleté, with high subject satisfaction and a favorable safety profile. Décolleté will be the lead indication for phase II, targeting a large unmet need.
-
Q2 2024 saw 55% sequential revenue growth, 91% gross margin, and high patient compliance for VYJUVEK. Strong U.S. launch fundamentals, robust cash reserves, and progress toward EU and Japan launches in 2025 position the company for continued growth.
-
High compliance and rapid access have driven strong commercial progress, with 60% market penetration targeted within two years. International expansion is on track, and a diversified pipeline supports long-term growth, including a $1B+ peak sales forecast for the lead indication.